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Abstract
The adult rat brain subventricular zone (SVZ) contains proliferative precursors that migrate to the olfactory bulb
(OB) and differentiate into mature neurons. Recruitment of precursors constitutes a potential avenue for brain
repair. We have investigated the kinetics and cellular specificity of transgene expression mediated by AAV2/1
vectors (i.e., adeno-associated virus type 2 pseudotyped with AAV1 capsid) in the SVZ. Self-complementary (sc)
and single-stranded (ss) AAV2/1 vectors mediated efficient GFP expression, respectively, at 17 and 24 hr post-
injection. Transgene expression was efficient in all the rapidly proliferating cells types, that is, Mash1 + precursors
(30% of the GFP + cells), Dlx2 + neuronal progenitors (55%), Olig2 + oligodendrocyte progenitors (35%), and
doublecortin-positive (Dcx + ) migrating cells (40%), but not in the slowly proliferating glial fibrillary acidic protein-
positive (GFAP + ) neural stem cell pool (5%). Because cell cycle arrest by wild-type and recombinant AAV has been
described in primary cultures, we examined SVZ proliferative activity after vector injection. Indeed, cell prolif-
eration was reduced immediately after vector injection but was normal after 1 month. In contrast, migration and
differentiation of GFP + precursors were unaltered. Indeed, the proportion of Dcx + cells was similar in the injected
and contralateral hemispheres. Furthermore, 1 month after vector injection into the SVZ, GFP + cells, found, as
expected, in the OB granular cell layer, were mature GABAergic neurons. In conclusion, the rapid and efficient
transgene expression in SVZ neural precursors mediated by scAAV2/1 vectors underlines their potential use-
fulness for brain repair via recruitment of immature cells. The observed transient precursor proliferation inhibition,
not affecting their migration and differentiation, will likely not compromise this strategy.
Introduction
The neurogenic pathway of the adult rat subventricularzone (SVZ) consists of several immature cell types at
various stages of differentiation and with different prolifera-
tive rates: (1) slowly proliferative (type B) cells expressing
glial fibrillary acidic protein (GFAP), (2) rapidly dividing
‘‘transit-amplifying’’ (type C) cells expressing Ascl1 (also
called Mash1) and generating both Dlx2-positive neuronal
progenitors and Olig2-positive oligodendrocyte progenitors
(Kim et al., 2007, 2011), and (3) migrating (type A) neuroblasts
characterized by the expression of doublecortin (Dcx). It
should be noted that Mash1/Ascl1, Dlx2, and Dcx marker
expression in the progenitors is partially overlapping (Kim
et al., 2007). The latter progenitors migrate through the rostral
migratory stream (RMS) to the olfactory bulb (OB) (Alvarez-
Buylla and Garcia-Verdugo, 2002), where they differentiate
into various types of mature neurons. By selective killing of
type C cells or by cell fate mapping, it has been shown that
type B cells are the ancestor of type C and type A cells
(Doetsch et al., 1999; Garcia et al., 2004) and that type A neu-
roblasts and their descendant OB differentiated neurons
originate from Ascl1 transit-amplifying type C progenitors
(Kim et al., 2007).
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Gene transfer into SVZ neural stem cells before their mi-
gration has been proposed with the purpose of recruiting
these cells for repair of CNS lesions (Fallon et al., 2000;
Chmielnicki et al., 2004; Cho et al., 2007; Henry et al., 2007).
Retroviral and lentiviral vectors, which integrate into the
cellular genome, have been used for tracing and fate analysis
of SVZ neural stem cells (Smith and Luskin, 1998). Because of
their requirement for cell division, retroviral vectors (Goldman
et al., 1993) have allowed the specific labeling of type C cells
and, to a lesser extent, slowly proliferating GFAP-positive
type B cells. Lentiviral vectors, which can infect both dividing
and nondividing cells, were superior in transducing type B
neural stem cells, hence ensuring long-term labeling of the
whole pathway (Consiglio et al., 2004; Geraerts et al., 2006).
However, for therapeutic gene delivery, the use of a
nonintegrative vector would be preferred in order to mini-
mize the risk of insertional mutagenesis in dividing cells
(Yanez-Munoz et al., 2006). Recombinant AAV2/1 vectors
(i.e., adeno-associated virus type 2 pseudotyped with AAV1
capsid) were previously shown to efficiently transduce cells
of the SVZ, which later on to migrate to the OB (Wang et al.,
2003). However, the delay in obtaining detectable transgene
expression in the brain, mediated by single-stranded
rAAV2/1 vectors (ssAAV2/1), was shown to be 4 days
postinjection (Reimsnider et al., 2007). At this time point, a
significant fraction of the initially infected cells is expected to
have migrated away from the SVZ (Craig et al., 1999). Self-
complementary AAV (scAAV) vectors, which were shown to
shorten the delay for transgene expression in the brain
(McCarty et al., 2001, 2003; McCarty, 2008), could constitute
an interesting alternative.
Because inhibition of the proliferation of fibroblasts
(Hermanns et al., 1997; Kube et al., 1997), keratinocytes (Alam
et al., 2006; Alam and Meyers, 2009), as well as grafted neural
stem cell primary cultures (Wu et al., 2002) by wild-type or
recombinant AAV2 has been repeatedly documented, it was
of interest to study the potential interactions between
rAAV2/1 vectors and the proliferative cells present in adult
brain neurogenic niches.
Therefore, in the present study, we have characterized the
kinetics and cell type specificity of rAAV2/1-mediated gene
transfer in the SVZ neurogenic niche as well as the prolifera-
tion, migration, and differentiation properties of transduced
cells. Single-stranded AAV2/1 and scAAV2/1 vectors medi-
ated detectable gfp transgene expression in the SVZ as early as
24 and 17 hr postinjection, respectively. All types of progenitors
were transduced, with the largest proportion of green fluo-
rescent protein (GFP)-positive cells harboring the Dlx2 marker
of transit-amplifying neuronal progenitors. A partial (30%)
inhibition of cell proliferation was observed in the transduced
area shortly after virus infusion. This inhibitory effect was
transient because, 1 month after vector injection, the number of
proliferating cells was equivalent to that of the control. In ad-
dition, the percentage of migrating Dcx-positive neuroblasts as
well as the localization and differentiation pattern of newly
generated neurons in the OB were not altered.
Materials and Methods
Plasmids and viruses
Recombinant scAAV2/1 or ssAAV2/1 virus expressing
the enhanced green fluorescent protein (eGFP)-encoding re-
porter gene under the control of the cytomegalovirus (CMV)
promoter was produced by cotransfection of HEK-293T
cells with pHpaItrs (McCarty et al., 2003) or pTR-eGFP
(Tenenbaum et al., 1999), respectively, and pDP1rs (Grimm
et al., 2003) (purchased from Plasmid Factory, Heidelberg,
Germany). Briefly, 3 lg of pTR-eGFP or pHpaItrs and 10 lg
of pDP1rs were transfected into 5 · 106 cells (per 10-cm plate
seeded 1 day previously) by the calcium phosphate copre-
cipitation method. The cell pellets from 20 plates were har-
vested, treated with Benzonase, and purified by iodixanol
gradient followed by QXL chromatography (i.e., chroma-
tography on Q Sepharose XL [GE Healthcare Life Sciences,
Piscataway, NJ]) (Zolotukhin et al., 1999). The virus was
microconcentrated and diluted into Dulbecco’s phosphate-
buffered saline (D-PBS), using a Centriplus centrifugal con-
centrator (EMD Millipore, Billerica, MA).
Titers were measured by real-time PCR as described in
www.isbiotech.org/ReferenceMaterials/pdfs/AAV2_RSS_
genome_copy_titration_QPCR.pdf (International Society for
BioProcess Technology, 2011).
Briefly, the method was first established with rAAV se-
rotype 2 reference standard (Lock et al., 2010). Viral particles
were digested with DNase I at 10 U per 5 ml of virus diluted
in 50 ml of DNase digestion buffer (13 mM Tris-HCl [pH 7.5],
5 mM MgCl2, and 0.12 mM CaCl2). Serial dilutions of the virus
were subjected to qPCR, using qPCR master mix (Applied
Biosystems/Life Technologies, Foster City, CA), forward
primer 5¢-AGCAATAGCATCACAAATTTCACAA-3¢, reverse
primer 5¢-CCAGACATGATAAGATACATTGATGAGTT-3¢,
and internal fluorescent probe 6FAM-AGCATTTTTTTCACT
GCATTCTAGTTGTGGTTTGTC-TAMRA (Eurogentec, Liège,
Belgium). Titers, expressed as viral genomes per milliliter,
were as follows: ssAAV2/1-CMV-eGFP, 4.3 · 1011; scAAV2/
1-CMV-eGFP, 2.1 · 1010.
The amount of viral capsids in the ssAAV2/1-CMV-eGFP
viral preparation was found to be 5.9 · 1012 per milliliter (as
evaluated by ELISA according to the recommendations of
the manufacturer (Progen, Heidelberg, Germany).
Surgical procedures
Adult female Wistar rats (250 g; Charles River, France) were
used for unilateral intracerebral injections (Bockstael et al., 2011).
Briefly, the animals were anesthetized with a mixture of keta-
mine (Ketalar, 100 mg kg- 1, intraperitoneal) and xylazine
(Rompun, 10 mg kg- 1, intraperitoneal) (Bayer, Leverkusen,
Germany). Injections were made according to coordinates de-
fined by Paxinos and Watson (1986), using a Kopf stereotaxic
apparatus (David Kopf, Tujunga, CA). Viral particles diluted in
2ll of D-PBS (Lonza Group, Basel, Switzerland) were infused
into the medial part of the dorsal striatum, using a motor-
driven Hamilton syringe (0.2 ll/min) equipped with a 30-gauge
needle, at the following coordinates: anteroposterior (AP),
0 mm; lateral (L), - 2.2 mm relative to bregma; and dorsoventral
(DV), - 4.2 mm relative to the cerebral surface (Paxinos and
Watson, 1986). After injection, the needle was left in place for
5 min in order to allow diffusion of the viral suspension in the
parenchyma. The needle was then slowly removed.
Animals were maintained, four in each cage, in a 12:12 hr
light–dark cycle with free access to rat chow and water.
Experimental procedures were conducted with the approval
of the Belgium Biosafety Advisory Committee and the ethics
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committee of the Faculty of Medicine (Commission d’Ethi-
que du Bien-Être Animal [CEBEA], Université Libre de
Bruxelles [ULB]).
Animals were killed with an overdose of anesthetic (ke-
tamine, 200 mg kg - 1; and xylazine, 20 mg kg - 1) at the indi-
cated time after virus injection. For immunohistological
analysis, animals were perfused through the ascending aorta
first with 150–200 ml of saline (0.9% NaCl), and then with
200 ml of 4% paraformaldehyde in 0.1 M phosphate buffer
(PF4). After overnight fixation in PF4 at 4C, brains were
transferred to PBS and stored at 4C.
5-Bromo-2 ¢-deoxyuridine-5¢-monophosphate
When indicated, 5-bromo-2¢-deoxyuridine-5¢-monopho-
sphate (BrdU, 20 mg kg–1; Sigma-Aldrich, St. Louis, MO) was
injected intraperitoneally twice per day.
To determine the proliferative index, BrdU (20 mg kg–1)
was injected three times intraperitoneally, that is, 20, 4, and
2 hr before surgery. BrdU (1 mg ml–1) was also given in
drinking water containing sucrose (30 g liter–1) during the
night before surgery (from 20 to 4 hr before surgery).
Immunohistochemistry
For GFP staining, vibrating blade microtome sections
(50 lm) were sequentially incubated (1) for 30 min in 3%
H2O2 in TBS (10 mM Tris, 0.9% NaCl; pH 7.6), (2) for 1 hr in
THST (50 mM Tris, 0.5 M NaCl, 0.5% Triton X-100; pH 7.6)
containing 10% horse serum, (3) overnight at 4C with
polyclonal rabbit anti-GFP (Clontech, Palo Alto, CA) diluted
1:3000 in THST containing 5% horse serum, and (4) for 2 hr at
room temperature with donkey anti-rabbit IgG conjugated
with biotin (Amersham/GE Healthcare, Munich, Germany)
diluted 1:600 in THST containing 5% horse serum. The per-
oxidase staining was revealed with an VECTASTAIN Elite
ABC kit and diaminobenzidine (Vector/NTL Laboratories,
Brussels, Belgium), according to the manufacturer’s protocol.
Sections were mounted on gelatin-coated slides, dehydrated,
and mounted with DPX mounting fluid (Sigma-Aldrich).
Sections were photographed with a Zeiss Axiophot 2 mi-
croscope (Carl Zeiss, Göttingen, Germany).
To determine transduction volumes, surfaces of labeled
SVZ were first evaluated (every fifth section) with the
AxioVision program (version 4.7.1; Carl Zeiss). Volumes (lm3)
were calculated by adding the surfaces of positive sections
and multiplying by the section thickness (50 lm) and by 5.
Immunofluorescence
Coronal sections (50 lm) obtained with a vibrating blade
microtome (Leica Microsystems, Wetzlar, Germany) were
sequentially incubated (1) for 2 hr in THST containing 10%
horse serum, (2) for 16 hr at 4C with polyclonal rabbit anti-
GFP IgG (Molecular Probes/Life Technologies, Eugene, OR)
diluted 1:3000 in THST containing 5% horse serum, (3) for
2 hr at room temperature with biotin-conjugated donkey
anti-rabbit IgG (Amersham/GE Healthcare) diluted 1:600 in
THST containing 5% horse serum, and (4) for 2 hr at room
temperature with streptavidin-conjugated cyanine 2 (Cy2;
Jackson ImmunoResearch, West Grove, PA) diluted 1:300 in
THST containing 5% horse serum. Three washings in TBS
(10 min each) were performed between each step.
For double immunofluorescence against NeuN (neuronal
nuclear antigen; mature neurons), glutamic acid decarboxylase-
67 (GAD67; GABAergic neurons), and GFAP (astrocytes and
neural stem cells), GFP immunofluorescence was combined
with mouse monoclonal anti-NeuN (diluted 1:200; Chemicon/
EMD Millipore), mouse monoclonal anti-GAD67 (diluted
1:500; Chemicon/EMD Millipore), or mouse monoclonal anti-
glial fibrillary acid protein (GFAP, diluted 1:200; Chemicon/
EMD Millipore) antibodies followed by donkey anti-mouse
IgG coupled to cyanine 3 (Cy3, diluted 1:200; Jackson Im-
munoResearch) in THST containing 5% horse serum.
For double immunofluorescence directed against Dcx
(migrating cells), GFP immunofluorescence was combined
with guinea pig polyclonal antibody anti-Dcx (diluted 1:300;
Chemicon/EMD Millipore) followed by donkey anti-guinea
pig IgG coupled to Cy3 (diluted 1:200; Jackson Im-
munoResearch) in THST containing 5% horse serum.
For double immunofluorescence directed against GFP and
Olig2 (oligodendrocyte progenitors), a chicken monoclonal
anti-GFP antibody (Abcam, Cambridge, UK) at a 1:1000 di-
lution was combined with rabbit polyclonal anti-Olig2 IgG
(diluted 1:500; Chemicon/EMD Millipore) in PBS containing
5% horse serum and 0.1% Triton X-100 and incubated for
16 hr at 4C. The primary antibodies were detected with
biotin-conjugated donkey anti-rabbit IgG (diluted 1:200;
Amersham/GE Healthcare) and a goat anti-chicken IgG
conjugated with Alexa 488 (diluted 1:1000; Molecular
Probes/Life Technologies) in PBS containing 5% horse serum
and 0.1% Triton X-100, 2 hr at room temperature, and then
incubated with streptavidin coupled to Cy3 (diluted 1:600;
Jackson ImmunoResearch) in PBS containing 5% horse
serum and 0.1% Triton X-100, 2 hr at room temperature.
For double immunofluorescence directed against GFP
and Dlx2, a chicken monoclonal anti-GFP antibody (Abcam)
at a 1:1000 dilution was combined with rabbit anti-Dlx2
IgG (ab30339, diluted 1:200; Abcam) followed by a Cy3-
coupled donkey anti-rabbit IgG (diluted 1:500; Jackson Im-
munoResearch).
For double immunofluorescence directed against GFP and
Mash1, GFP immunofluorescence was combined with a mouse
anti-Mash1 IgG1 (clone 24B72D11.1, diluted 1:100; BD Bio-
sciences, San Jose, CA) followed by a biotinylated rat anti-mouse
IgG1 (clone A85-1, diluted 1:200; BD Biosciences) and strepta-
vidin coupled to Cy3 (diluted 1:200; Jackson ImmunoResearch).
For BrdU immunofluorescence, sections were first treated
as follows to allow the antibody to reach the nucleus: sec-
tions were incubated with 1 N HCl for 10 min on ice, trans-
ferred to 2 N HCl for 10 min at room temperature, and then
further incubated at 37C for 20 min. Sections were then
transferred into sodium borate (0.1 M, pH 8.5) for 15 min.
For BrdU/GFP and BrdU/Ki67 double immunofluores-
cence, a rat monoclonal anti-BrdU antibody (diluted 1:200;
Abcam) was combined with rabbit polyclonal anti-GFP (di-
luted 1:3000; Molecular Probes) or rabbit polyclonal anti-
Ki67 (diluted 1:500; Novocastra, Newcastle upon Tyne, UK)
antibody in THST containing 5% horse serum, 16 hr at 4C. A
goat anti-rat IgG coupled to Cy3 (diluted 1:600; Jackson
ImmunoResearch) was used to detect anti-BrdU primary
antibodies. A goat anti-rabbit IgG coupled to biotin (diluted
1:500; Jackson ImmunoResearch) followed by incubation in
streptavidin coupled to Alexa 647 (diluted 1:500; Jackson
ImmunoResearch) was used to detect anti-Ki67 primary
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antibodies. Alternatively, a goat anti-rabbit IgG coupled to
biotin (diluted 1:500; Jackson ImmunoResearch) followed by
incubation in streptavidin coupled to Cy2 (diluted 1:500;
Jackson ImmunoResearch) was used to detect anti-GFP pri-
mary antibodies.
For nuclear counterstainings, sections were incubated for
30 min with Hoechst 33258 dye (Sigma-Aldrich) diluted to
1 lg/ml in TBS.
Three washings in TBS of 10 min were performed between
each step.
Sections were mounted on gelatin-coated slides, using
Glycergel mounting fluid for fluorescence (Dako, Glostrup,
Denmark).
Confocal microscopy
Colabeling and proliferative index analyses were per-
formed on pictures taken of at least three different sections,
using an LSM 510 NLO multiphoton confocal microscope
fitted on an Axiovert M200 inverted microscope equipped
with C-Apochromat · 40/1.2 NA water immersion objec-
tives (Carl Zeiss, Jena, Germany).
The 488-nm excitation wavelength of the Argon II laser, a
main dichroic HFT 488 beam splitter, and a bandpass emis-
sion filter (BP500–550 nm) were used for selective detection
of the green fluorochrome (Cy2). The 543-nm excitation
wavelength of the HeNe1 laser, a main dichroic HFT 488/
543/633 beam splitter, and a long-pass emission filter
(BP565–615 nm) were used for selective detection of the red
fluorochrome (Cy3). The 633-nm excitation wavelength of
the HeNe2 laser, a main dichroic HFT 488/543/633 beam
splitter, and a long-pass emission filter (BP650–700 nm) were
used for selective detection of the far-red fluorochrome
(Alexa 647). The nuclear stain Hoechst/DAPI was excited in
multiphotonic mode at 760 nm with a Mai Tai tunable
broadband laser (Spectra-Physics, Darmstadt, Germany) and
detected with a main dichroic HFT KP650 beam splitter and
a bandpass emission filter (BP435–485 nm).
Optical sections (2 lm thick, 512 by 512 pixels) were col-
lected sequentially for each fluorochrome. Z-stacks with a
focus step of 1 lm were collected.
The data sets generated were merged and displayed with
Zeiss ZEN 2009 software and exported in LSM image format.
Countings were performed with ImageJ 1.46a software
(National Institutes of Health, Bethesda, MD). Figures were
prepared with Adobe Photoshop CS3 software (Adobe, San
Jose, CA).
Proliferative index
The proliferative index is the ratio of the number of pro-
liferating cells (detected by expression of Ki67 protein) to the
number of cells previously in proliferation, measured by the
incorporation of BrdU during a given time lapse.
Apoptosis detection
To evaluate apoptosis induction, an in situ cell death de-
tection kit (Roche Applied Science, Indianapolis, IN) was
used according to the manufacturer’s recommendations.
Briefly, the animals were killed by decapitation 24 hr after
surgery, after the injection of an overdose of anesthetic
(ketamine, 200 mg kg - 1; and xylazine, 20 mg kg - 1). The
brains were rapidly frozen to - 20C, using dry ice in a bath
of methylbutane, and then stored at - 80C. Cryosections
(16 lm thick) were made with a Leica cryostat and placed
on Superfrost Plus slides. Terminal deoxynucleotidyl-
transferase-mediated dUTP nick end-labeling (TUNEL) de-
tection was done with the in situ cell death detection kit
(Roche Applied Science) according to the manufacturer’s
recommendations for difficult tissues. TUNEL-positive cells
were quantified with a Zeiss Axiophot 2 microscope equip-
ped with fluorescein isothiocyanate (FITC) and tetra-
methylrhodamine isothiocyanate (TRITC) filters (Carl Zeiss,
Göttingen, Germany) on five sections surrounding the in-
jection site, covering 400 lm along the anteroposterior axis.
Cells were counted in the SVZ ipsilateral and contralateral to
the injection site. Ipsilateral counts were divided by contra-
lateral counts to normalize small anteroposterior differences
between animals.
Statistical analyses
Means – standard deviations are shown. Data were ana-
lyzed using Prism 3.0 software (Graph Pad Software, San
Diego, CA). Unpaired Student t tests and one-way analysis
of variance (ANOVA) were performed.
Virus irradiation
ssAAV2/1-CMV-eGFP diluted in D-PBS (Lonza Group)
was irradiated with a UV Stratalinker chamber (Stratagene/
Agilent Technologies, La Jolla, CA) at a dose of 4800 J/m2.
Irradiation completely abolished GFP expression as assessed
by infection of HEK-293T cells and fluorescence-activated
cell-sorting (FACS) analysis.
Bovine serum albumin injections
Protein concentration of the stock of ssAAV2/1-CMV-
eGFP, measured with a Micro BCA protein assay kit (Pierce/
Thermo Fisher Scientific, Rockford, IL) according to the
manufacturer’s recommendations, was found to be 20 lg/
ml. A solution of bovine serum albumin (BSA) diluted to
20 lg/ml in D-PBS was injected in the vicinity of the SVZ
according to the method described above for viral injections
(see surgical procedures).
Results
Fast and efficient transduction of subventricular zone
neural precursors by rAAV2/1
It has been previously reported that injection of rAAV2/1
vectors using the CMV promoter into the striatum of mice
(Passini et al., 2003; Wang et al., 2003) and rats (Bockstael
et al., 2008) resulted in efficient transduction of the SVZ. In
these studies, GFP-positive cells were found in the OB, the
region in which neural stem cells of the SVZ terminally dif-
ferentiate.
Because of the rapid dynamics of the SVZ–OB pathway,
most type C progenitors and type A neuroblasts are expected
to have migrated away in the RMS within a few days (Craig
et al., 1999). Therefore, we evaluated transduction efficiency
of self-complementary and single-stranded AAV2/1 vectors
during the first 4 days after injection of 4.3 · 107 genome
copies (low dose) of each virus into the medial part of the
RAPID GENE EXPRESSION IN SVZ WITH AAV2/1 745
dorsal striatum (Fig. 1a). Transduction efficiency was eval-
uated immunohistochemically as the volume of SVZ staining
positive for GFP (Fig. 1b).
scAAV2/1 transduced the SVZ as early as 17 hr after
vector injection, and maximal transduction efficiency was
reached at 24 hr (Fig. 1b). In contrast, ssAAV2/1-transduced
cells in the SVZ were detected only 24 hr postinjection, and
the highest efficiency was reached at 48 hr (Fig. 1b). Trans-
duction decreased at 96 hr, the decrease being more pro-
nounced for the ssAAV2/1 vector (Fig. 1b), and was low at 1
month (data not shown). Increasing the amount of ssAAV2/
1 by 20-fold (8.6 · 108 genome copies, high dose) did not
result in a significant improvement of transduction efficiency
(Fig. 1b).
Characterization of rAAV2/1-transduced cells
in the subventricular zone
During their commitment from neural stem cells to mature
neurons, immature cells express various and sometimes
overlapping markers (Kim et al., 2007; Jones and Connor,
2011). To characterize the cellular specificity of rAAV2/1-
mediated transgene expression, animals were killed 2 days
after injection of vectors in the vicinity of the SVZ (at the time
at which the number of GFP + cells is maximal for both
vectors). Vibrating blade microtome sections were subjected
to double immunofluorescence for GFP and, respectively,
GFAP (labeling slowly proliferating type B cells), Mash1
(labeling rapidly proliferating type C cells), Dlx2 (labeling
FIG. 1. Transduction of the subventricular zone by rAAV2/1. A low dose of scAAV2/1-CMV-eGFP or ssAAV2/1-CMV-
eGFP or a high dose of ssAAV2/1 was injected into the medial striatum. (a) Seventeen, 24, 48, and 96 hr after injection of a
low dose of the indicated vector, 50-lm vibrating blade microtome sections were labeled with anti-GFP antibodies and
photographed with a Zeiss Axioplan 2 microscope and a · 20 objective (scale bars, 250 lm). (b) Transduction volumes after
injection of a low dose of scAAV2/1 (open columns), a low dose of ssAAV2/1 (gray columns), and a high dose of ssAAV2/1
(solid columns) were quantified by the AxioVision program to evaluate the GFP-positive surfaces in the subventricular zone
(SVZ) and multiplying by the thickness of the sections (50 lm) and the number of sections between two counted sections
(five) (see Materials and Methods).
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rapidly proliferating type C neuronal precursors subpopu-
lation), Olig2 (labeling a rapidly proliferating type C oligo-
dendrocyte precursor sub-population), or doublecortin (Dcx,
labeling migrating type A neuroblasts) (Fig. 2a).
As shown in Fig. 2b, 2 days postinjection of ssAAV2/1
(n = 4), 29.09 – 3.23% of GFP + cells in the SVZ (as delineated
by Hoechst 33258 staining; data not shown) were Mash1 + ,
57.7 – 9.92% were Dlx2 + , and 36.97 – 6.9% were Olig2 + ,
44.71 – 2.08% were Dcx + , whereas only 5.85 – 0.45% were
GFAP + . Similar proportions of Mash1 + cells (27.49 – 3.58%,
n = 4, p = 0.532, Student t test), Dlx2 + cells (52.28 – 3.01%, n = 3,
p = 0.1974, Student t test), Olig2+ cells (29.41 – 7.64 %, n = 7,
p = 0.1379, Student t test), and GFAP + cells (4.69 – 1.46%,
n = 4, p = 0.1792, Student t test) were transduced by the
scAAV2/1 vector. Proportions of GFP + cells expressing Dcx
were significantly different ( p = 0.007, Student t test) between
FIG. 2. Characterization of scAAV2/1-CMV- and ssAAV2/1-CMV-eGFP-transduced cells in the adult SVZ. Two days after
injection of scAAV2/1-CMV-eGFP and ssAAV2/1-CMV-eGFP (low dose) into the medial striatum, 50-lm vibrating blade
microtome sections of the forebrain were colabeled with anti-GFP (green fluorescence) and anti-GFAP, anti-Mash1, anti-Dlx2,
anti-Olig2, or anti-Dcx (red fluorescence) antibodies. (a) Confocal pictures show GFP and cell-specific markers in double-
labeled cells (yellow) 2 days after scAAV2/1-CMV-eGFP (low dose) injection. Arrows indicate double-labeled cells. Scale
bars, 50 lm. (b) The proportions of colabeled cells relative to the total number of GFP + cells were significantly different
between the two vectors for doublecortin but not for the GFAP, Mash1, Dlx2, or Olig2 markers. (c) The proportions of
colabeled cells relative to the total number of specific progenitor marker-positive cells were significantly different between the
two vectors for Mash1 but not for the Olig2 or doublecortin markers. Open columns, scAAV2/1-CMV-eGFP; solid columns,
ssAAV2/1-CMV-eGFP. Data are expressed as means – SD. **p < 0.01.
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ssAAV2/1-injected animals and scAAV2/1-injected animals
(44.7 – 2.1% [n = 4] and 29.64 – 8.33% [n = 7], respectively).
Efficacy of rAAV2/1-mediated gene transfer
into SVZ progenitors
To determine the efficacy of both scAAV2/1 and ssAAV2/
1 to mediate gene transfer into SVZ progenitor cells, we
quantified the proportion of specific progenitor subtypes also
expressing GFP in the transduced area (only sections harbor-
ing GFP-positive cells, corresponding to approximately 30% of
the complete SVZ, were taken into account).
As shown in Fig. 2c, 48 hr after injection of scAAV2/1,
42.13 – 2.4% of Mash1 + cells also express GFP (n = 4),
41.12 – 7.19% of Olig2 + cells were also GFP + (n = 7), and
66.39 – 16.23% of DCX + cells also express GFP (n = 8). Similar
proportions of Olig2 + cells and DCX + cells were found to
express GFP (37.91 – 2.55%, n = 4, p = 0.4183, Student t test and
52.2 – 1.21%, n = 4, p = 0.1192, Student t test, respectively) 2
days after ssAAV2/1 injections (low dose) whereas Mash1 +
cells were less efficiently transduced by ssAAV2/1 than by
scAAV2/1 (21.62 – 8.25%, n = 4, p = 0.0031, Student t test).
Because of their high density (see Fig. 2a), reliable count-
ing of Dlx2 + neuronal progenitors was unfeasible.
Inhibition of SVZ proliferative activity by rAAV2/1 virus
Because BrdU is incorporated mainly by transit-amplifying
type C cells, it is expected that when Dlx2 + transduced cells
migrate to the OB and differentiate into postmitotic neurons,
they will still harbor BrdU in their genome. We thus searched
for BrdU/GFP double-labeled cells in the OB 5 weeks after
injection of 4.3 · 107 genomes of ssAAV2/1 and BrdU injec-
tions at various time points (Fig. 3a).
When BrdU was administered for 5 days starting 5 days
before virus injection, 83.12 – 11.07% of the GFP + cells found
in the OB 5 weeks later were colabeled with anti-BrdU an-
tibodies (n = 4). In contrast, when BrdU was injected for 5
days starting immediately after virus injection, a highly
significant decrease in GFP-expressing cells colabeling with
BrdU (10.5 – 6.21%, n = 4, p < 0.0001, Student t test; Fig. 3a)
was observed.
In contrast, the overall BrdU-labeled cell density in the OB
5 weeks after virus injection was similar in both groups
( p = 0.5124, Student t test; data not shown). This means that
the observed drastic reduction in BrdU labeling in GFP + cells
in the OB is not related to the BrdU delivery time schedule
but to the rAAV2/1 infection.
To further assess the effect of rAAV2/1 on SVZ progenitor
proliferation, the proliferative index of the SVZ was mea-
sured 24 hr after vector injection. We observed a highly sig-
nificant ( p < 0.0001, one-way ANOVA) decrease in the ratio
of Ki67 + versus BrdU + cells in the SVZ after injection of
4.3 · 107 viral genomes of ssAAV2/1-CMV-eGFP (n = 7) or
scAAV2/1-CMV-eGFP (n = 5) compared with animals in-
jected with vehicle (D-PBS, n = 10): respectively, 87.69 – 7.4%,
89.18 – 4.2%, and 131.12 – 16.87% (Fig. 3b).
rAAV2/1 virus does not increase apoptosis in the SVZ
Cell numbers in the SVZ are known to be controlled by a
low level of apoptosis (Ricard et al., 2006). To assess whether
the observed reduction of the proliferative index could be
FIG. 3. Inhibition of SVZ proliferative activity by rAAV2/
1. (a) Five weeks after injection of ssAAV2/1-CMV-eGFP
(low dose) into the medial striatum, a significantly different
proportion of double-labeled cells positive for GFP and BrdU
relative to the total number of GFP + cells was found in the
OB of animals receiving BrdU for 5 days before virus injection
or immediately after vector injection. Open column, BrdU
preinjection; solid column, BrdU postinjection. (b) The pro-
liferative index of the SVZ was measured around the injection
site 24 hr after injection of virus diluent buffer (sham injec-
tion), ssAAV2/1-CMV-eGFP, irradiated ssAAV2/1-CMV-
eGFP, scAAV2/1-CMV-eGFP, or 0.4 lg of unspecific proteins
close to the SVZ. A significant reduction in the proliferative
index was found between the sham-injected group and the
other groups and between the BSA-injected group and the
other groups. No significant difference was found between
the ssAAV2/1-CMV-eGFP-injected animals, the irradiated
ssAAV2/1-CMV-eGFP-injected animals, and the scAAV2/
1-CMV-eGFP-injected animals or between the sham-injected
group and the BSA-injected group. Data are expressed as
means – SD. ***p < 0.0001.
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due to increased apoptotic neural precursor cell death,
TUNEL fluorescence staining of the SVZ was performed
shortly (24 hr) after rAAV2/1 injection. As expected, few
TUNNEL-positive cells were observed in the SVZ. However,
there was no significant difference (p = 0.3827, Student t test,
data not shown) between the ratio of TUNEL-positive nuclei
observed ipdsilateral and contralateral to the injection side of
virus injected (n = 5) and sham (D-PBS)-injected animals
n = 4). Let us notice that numerous positive nuclei were
observed around the needle track of both virus- and PBS-
injected animals. As expected DNase-treated sections (posi-
tive control) harboured positive nuclei on the whole sections.
Proliferation inhibition in the SVZ does not require
vector-derived protein synthesis
To evaluate the contribution of transgene expression to
this effect, 5.9 · 108 viral capsids (corresponding to 4.3 · 107
viral genomes) of UV-irradiated ssAAV2/1-CMV-eGFP
(4800 J/m2) were injected in the vicinity of the SVZ. (Note:
The UV-irradiated virus did not express GFP, as demon-
strated by the absence of green fluorescent cells after infec-
tion of etoposide-treated HEK-293T cells; data not shown.) A
similar drop in the proliferative index ( p > 0.05, one-way
ANOVA test) as with nonirradiated virus was observed
(81.68 – 11.29%, n = 4; Fig. 3b).
Proliferation inhibition in the SVZ is not due
to unspecific high protein loads
To evaluate the contribution of a high amount of protein
to this proliferation inhibition effect, 0.4 lg (corresponding to
the capsid protein concentration of the low-dose virus) of
unspecific proteins (BSA) was injected in the vicinity of the
SVZ. The proliferative indexes observed in the SVZ of the
BSA-injected animals (154.46 – 27.07%, n = 4) and D-PBS-
injected animals (131.12 – 16.87%, n = 10) were similar ( p > 0.05,
one-way ANOVA test; Fig. 3b).
Proliferation inhibition in the SVZ is transient
The proliferative index is not suitable to assess the effect of
AAV2/1 injection on SVZ proliferation at later time points
since most BrdU-labeled cells have presumably migrated
away through the rostral migratory stream toward the OB.
We therefore injected a single pulse of BrdU (20 mg/kg, in-
traperitoneal) 4 weeks after virus injection and killed the
animals 24 hr later. BrdU + cell density was then calculated in
the ipsilateral and contralateral SVZ on three sections cov-
ering 500 lm along the anteroposterior axis around the in-
jection point. No significant difference was found ( p = 0.532,
Student t test; data not shown) between ipsilateral and
contralateral BrdU + cell density in the SVZ, indicating that
the proliferation rate of the SVZ had returned to normal 4
weeks after virus injection.
rAAV2/1 transduction of SVZ neural progenitors
does not modify the proportion of migrating neuroblasts
in the SVZ
To evaluate the effect of AAV2/1 injection on the pheno-
type of subventricular progenitors, we counted the number
of Dcx + cells in the injected SVZ and in the contralateral
SVZ. Dcx + cell counts were normalized by Mash1 + /Ascl1 +
cell numbers observed on adjacent sections. No difference
was found between the proportions of Dcx + cells on the
injected versus the contralateral side ( p = 0.2978; data not
shown), suggesting that AAV2/1 did not bias progenitor
fate.
rAAV2/1 transduction of SVZ neural progenitors does
not modify their terminal localization and differentiation
into the OB
It has been previously shown that most SVZ precursors
give rise to neurons of the OB granule cell layer, whereas
OB periglomerular neurons derive from RMS precursors
(Hack et al., 2005). Granule neurons are almost exclusively
GABAergic whereas among periglomerular neurons, only
40% are GABAergic (Parrish-Aungst et al., 2007).
Five weeks after injection of 4.3 · 107 viral genomes of
ssAAV2/1-CMV-eGFP (n = 5) or scAAV2/1-CMV-eGFP
(n = 4) close to the SVZ, GFP-positive cells were present in the
OB granule cell layer. The vast majority of transduced cells
were NeuN + (90.62 – 3.93% and 86.46 – 3.69% for ssAAV2/1
and scAAV2/1, respectively; Fig. 4a). As expected for newly
generated neurons originating from the periventricular
area (Kosaka et al., 1995), the majority of GFP + cells were
GABAergic, as shown by the colocalization with GAD67
FIG. 4. Characterization of transduced cells in the olfactory bulb after injection of rAAV2/1 into the medial striatum. Five
weeks after injection of ssAAV2/1-CMV-eGFP (low dose) close to the SVZ, 50-lm vibrating blade microtome sections of the
olfactory bulbs were colabeled with anti-GFP (green fluorescence) and anti-NeuN (a), anti-GFAP (b), or anti-GAD67 (c) (red
fluorescence) antibodies. Double-labeled cell bodies (yellow) were evidenced by confocal microscopy. Arrows indicate
double-labeled cells. Scale bars: 50 lm.
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(84.43 – 3.18% and 82.07 – 6.42% for ssAAV2/1 and scAAV2/
1, respectively; Fig. 4c), and tyrosine hydroxylase (TH) neg-
ative (data not shown). No GFP/GFAP-colabeled cells were
identified for either vector (Fig. 4b).
Discussion
It has been shown that rAAV2/1 vectors efficiently and
rapidly transduced neuronal progenitors of the adult rat SVZ
at various stages of their commitment: multipotent Mash1 +
neural precursors, Dlx2 + neuronal progenitors, and Dcx +
migrating neuroblasts. Oligodendroglial progenitors were
also transduced but less efficiently. In contrast, the pool of
GFAP + neural stem cells was poorly transduced. These data
are important for strategies aiming at the transient recruit-
ment of neuronal progenitors for brain repair (Fallon et al.,
2000; Chmielnicki et al., 2004; Cho et al., 2007) without af-
fecting the long-term normal function of the SVZ–OB path-
way. Furthermore, transgene expression started early after
vector injection, that is, 24 hr for single-stranded (ss) AAV2/
1 and 17 hr for self-complementary (sc) AAV2/1, a delay that
is compatible with the genetic modification of progenitors
before these migrate en route to the OB. These results are in
contrast with a previously published study showing that
neural progenitors isolated from fetal brain and cultured as
neurospheres are poorly susceptible to AAV-mediated gene
transfer (Hughes et al., 2002). However, cultured fetal neural
progenitors and adult neural progenitors in situ in the SVZ
environment could differ in terms of receptor expression,
proliferative state, and so on. Furthermore, AAV2/1 has not
been tested in this study. Notably, in another more recent
study, AAV6, which differs from AAV1 by only six amino
acids (Ng et al., 2010), mediated GFP expression in 10% of
cultured neural progenitors whereas AAV2 and AAV5 pro-
vided low (1%) efficiency.
A slow onset of transgene expression mediated by rAAV
vectors in the brain has been frequently described (Duan
et al., 2000; McCown, 2005). This delay was suggested to
reflect limiting steps such as viral particle intracellular traf-
ficking (Duan et al., 2000), uncoating of the virion (Thomas
et al., 2004), and second-strand synthesis (Ferrari et al., 1996;
Fisher et al., 1996). With the aim to transfer genes into neural
progenitors, which leave the SVZ and migrate through the
RMS within a few days (Craig et al., 1999), a vector able to
rapidly transduce these cells is required. Reimsnider and
colleagues (2007) have shown that rAAV2/1 mediates effi-
cient transgene expression in the striatum as early as 4 days
after injection and that the number of GFP-immunoreactive
cells observed at 4 days was equivalent to that observed at
later time points (up to 9 months). In the present report,
transduction efficiency of SVZ cells peaked as early as 24 and
48 hr postinjection of scAAV2/1 and ssAAV2/1 vectors, re-
spectively. This faster onset of expression observed in SVZ
precursors as compared with the striatum (present study, Fig.
1) (Reimsnider et al., 2007) could be related to the proliferative
state of the target cell population (Halbert et al., 1995). How-
ever, in contrast to the study by Halbert and colleagues, using
immortalized cell lines, another report using muscle primary
cultures suggests that the proliferative status does not affect
short-term gene transfer efficiency (Malik et al., 2000).
Self-complementary vectors have been demonstrated to
allow faster onset and higher efficiency of transgene ex-
pression in the brain (McCarty et al., 2003; McCarty, 2008).
Accordingly, in the present study, the delay in transgene
expression within the SVZ was longer for ssAAV2/1 than for
scAAV2/1, suggesting that second-strand synthesis is a
limiting step.
Globally at 48 hr postinjection, both vectors mediate sim-
ilar efficiency of transgene expression. However, when the
various cell types are examined separately, scAAV2/1 and
ssAAV2/1 mediate similar efficiency of gene transfer in
Dcx + (66 vs. 52%, NS) and Olig2 + (41 vs. 38%, NS) cells but,
in contrast, the proportion of Mash1 + cells expressing GFP
was significantly higher with the self-complementary vector
(42 vs. 22%; p < 0.005). These data could suggest that second-
strand synthesis is more limiting in Mash1 + cells than in the
other progenitor types because a cellular factor required for
second-strand synthesis is present in more limiting amounts
in these cells. Alternatively, it could be that in highly prolif-
erative Mash1 + cells, in which vector genomes are expected to
be rapidly diluted, the limiting genome copy number neces-
sary to obtain detectable transgene expression is more rapidly
reached with single-stranded AAV than with self-comple-
mentary AAV. In contrast, there is no difference between both
vectors in terms of the numbers of GFP + cells present in the
olfactory bulb 1 month postinjection. Altogether, these data
suggest that both vectors differ regarding the onset but not the
long-term stability of transgene expression.
The observed reduced proportion of Dcx + cells among
total GFP + cells with scAAV2/1 as compared with ssAAV2/
1 at 48 hr, as well as the slight tendency for reduced pro-
portions of double-labeled cells expressing Mash1, Dlx2,
and Olig2 markers, could reflect efficient transgene expres-
sion in differentiated brain cells with scAAV2/1 but not
with ssAAV2/1. Indeed, as clearly evidenced by GFP ex-
pression in the striatum, which does not contain progeni-
tors, numerous differentiated cells expressed the transgene
after scAAV2/1 but not ssAAV2/1 administration (see
Fig. 1, 48 hr).
It should be noted that the quantifications performed in
the SVZ were limited to the area in which the majority of
transgene expression was observed, which represents only
approximately one-third of the entire SVZ. If the entirety of
the SVZ is to be transduced, two or three injections at dif-
ferent anteroposterior coordinates should be performed. In-
deed, SVZ progenitors are found in a region covering
approximately 2–3 mm along the anteroposterior (AP) axis
and we have previously shown that rAAV2/1 injections into
the striatum result in high numbers of gfp-expressing cells in
a region covering approximately 1–1.5 mm along the AP axis
(Bockstael et al., 2008).
AAV vector genomes were shown to remain episomal in
rodent (Schnepp et al., 2003), macaque (Afione et al., 1996),
and human tissues (Afione et al., 1996; Schnepp et al., 2005). It
is therefore expected that when cells proliferate, genomes are
diluted and AAV-mediated transgene expression is lost.
However, with 107–108 viral genomes injected, the multi-
plicity of infection is presumably high at the injection site
and in the surrounding area. Hence, numerous rAAV ge-
nomes are expected to be present in the nucleus of each
transgene-expressing cell. Consequently, GFP + cells could
divide several times before losing transgene expression.
Interference of parvoviruses and in particular AAV and
AAV vectors with the cell cycle has repeatedly been reported
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(Winocour et al., 1988; Bantel-Schaal and Stohr, 1992; Kube
et al., 1997; Fragkos et al., 2008). Reduction of cell numbers in
fibroblast primary cultures by wild-type AAV2 virus was
shown to be due to accumulation of infected cells in the late S
and G2 phases (Winocour et al., 1988; Bantel-Schaal and
Stohr, 1992). On the basis of studies with UV-inactivated
virus, it has been suggested that viral gene expression was
not required (Winocour et al., 1988). Increased levels of the
cell cycle inhibitor p21WAF1 was demonstrated after AAV2
infection of primary human fibroblasts (Hermanns et al.,
1997) as well as primary human keratinocytes (Alam et al.,
2006). Recombinant AAV2 vector, devoid of viral coding
sequences, was also reported to inhibit fibroblast prolifera-
tion (Kube et al., 1997). Kube and colleagues suggested that
residual Rep protein attached to the capsid of recombinant
AAV might be responsible for this effect (Kube et al., 1997).
On the other hand, Fragkos and colleagues (2008) reported
that an AAV2 viral DNA sequence within the p5 promoter
was responsible for DNA replication inhibition followed by a
DNA-damaging response. However, this sequence is not
present in AAV vectors.
It was therefore important to assess whether the remark-
ably rapid and efficient transduction of dividing brain cells
could be accompanied by a perturbation of their cell cycle.
Indeed, in the present study, a partial inhibition of cell pro-
liferation was observed in the GFP-positive area of the SVZ,
shortly after virus infusion. This inhibitory effect was evi-
denced by two different methods: (1) on the basis of the
drastic reduction of the number of double-labeled BrdU-GFP
cells (but not of the total number of BrdU + cells) reaching the
OB when BrdU was given immediately after, as compared
with immediately before, infection; and (2) the reduction of
the proliferative index, consisting of the ratio of the number
of dividing (Ki67 + ) cells 24 hr postinfection and the basal
proliferation level as measured by the numbers of cells
having incorporated BrdU during 1 day before infection.
Altogether, those data suggest that the majority of the in-
fected progenitors stopped proliferating, whereas the unin-
fected cell population remained unaffected.
We first hypothesized that proliferation inhibition could
be related to the vector genome. We report that UV-irradiated
AAV2/1 vector similarly reduces the proliferative index,
suggesting it is not mediated by transgene expression. The
AAV genome has been shown to be the target of DNA repair
enzymes ( Jurvansuu et al., 2005). However, it was later
suggested that a sequence present in the p5 promoter, which
is absent in AAV vectors, is necessary for this interaction
(Fragkos et al., 2008). On the other hand, single-stranded and
self-complementary AAV genomes were shown to interact
differently with the DNA double-stranded break repair
machinery than single-stranded genomes (Cataldi and
McCarty, 2010). In our data, scAAV2/1 and ssAAV2/1
mediate similar proliferation inhibition, in favor of the DNA
structure not playing a major role.
In one report, a single-stranded 40-nucleotide G-rich
tetrad repeat sequence present in the AAV origin of repli-
cation has been shown to induce p53-dependent apoptosis of
human embryonic stem cell cultures (Hirsch et al., 2011). This
sequence might possibly inhibit progenitor cell division in
the present study. However, the TUNEL assay failed to
demonstrate increased apoptosis in the AAV2/1-injected
SVZ.
Alternatively, the precursor proliferation inhibition effect
could be protein mediated. We first excluded that it could
be explained by an unspecific high load of proteins as
shown by the absence of effect of an equivalent amount of
BSA. The inhibitory effect could be mediated by the capsid.
In particular, it could be due to a specific peptidic motif
inducing a cellular transduction signal pathway leading to
the increase of a cell cycle inhibitor such as, for example,
p21WAF1. In this context, it remains to be determined whe-
ther other capsid serotypes have similar effects. Last, it
cannot be excluded that Rep proteins produced during
the cotransfection of HEK-293T cells could be present in the
viral preparations and mediate cell cycle arrest in S phase
(Kube et al., 1997; Berthet et al., 2005). Unfortunately,
we have no data available about the purity of our vector
stocks. We thus cannot exclude the possibility that con-
taminants are responsible for progenitor proliferation inhi-
bition. However, we observed similar decreases in the
proliferative index in the SVZ when injecting similar doses
of vector stocks purified by the iodixanol:ion-exchange
method (our laboratory) and the CsCl2 gradient method
(Laboratoire de Thérapie Génique, Nantes, France) (data not
shown). Because it is unlikely that the same contaminants
are present in vector batches purified by totally different
methods, it is hypothesized that the here-reported absence
of effect mediated by bovine albumin in a similar concen-
tration as viral capsids reasonably excludes the possibility of
an unspecific effect of high protein load and points to
proliferation inhibition being related to an AAV component
rather than to a contaminant.
With the aim to recruit neural stem cells toward lesions, it
was also important to assess whether migration and differ-
entiation of the SVZ–OB progenitors could be affected by the
vector itself. After a transient phase of rapid proliferation,
progenitors gradually acquire migrating properties and
neuronal markers (Kim et al., 2007). Their final destination
and differentiation pattern depend on the initial location of
their ancestor neural stem cells (Hack et al., 2005). We show
that the percentage of migrating Dcx + cells relative to the
pool of Mash1 + neural precursors was unaltered by viral
transduction. Furthermore, the newly generated neurons
were located in the OB granular layer, expressed the GAD67
marker of GABAergic neurons, and were TH negative, as
expected for cells originating in the SVZ (Smith and Luskin,
1998).
The here-described inhibition of proliferation of immature
neuronal cells should be taken into account when interpret-
ing experiments aiming at the recruitment of SVZ neural
stem cells by AAV-mediated gene transfer (Henry et al.,
2007). It should be noted, however, that this inhibitory effect
is transient as demonstrated by the normal BrdU incorpo-
ration in the SVZ observed at 1 month postinjection of
rAAV2/1 (Henry et al., 2007). The restoration of SVZ pro-
liferative activity after 1 month presumably reflects the dy-
namics of the SVZ–OB pathway combined with the cellular
specificity of rAAV2/1-mediated gene transfer. Indeed, we
have shown that after 1 month, the transduced progenitors
have migrated to the OB, differentiated, and stopped di-
viding, whereas the SVZ progenitor population has pre-
sumably been reconstituted by the pool of GFAP + neural
stem cells that has not (or poorly) been transduced. Fur-
thermore, the transient inhibition of proliferation did not
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seem to interfere with the migration and differentiation of
neuroblasts to the OB.
In conclusion, the rapid and efficient transgene expression
in SVZ neural precursors is promising concerning the use of
scAAV2/1 vectors for the recruitment of SVZ neural pro-
genitors. The observed partial and transient inhibition of
proliferation not affecting precursor migration and differen-
tiation will likely not compromise the implementation of this
strategy.
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